Amgen Phase 3 DeLLphi-305: IMDELLTRA plus AZN Imfinzi cut death risk 58% in small cell lung cancer
Amgen Phase 3 DeLLphi-305: IMDELLTRA (tarlatamab) plus AstraZeneca's Imfinzi cut death risk 58% in first-line extensive-stage small cell lung cancer
- Median overall survival extended to 21.1 months vs. 12.7 months with IMDELLTRA plus Imfinzi maintenance therapy.
- Regimen used as first-line maintenance therapy in extensive-stage small cell lung cancer in the DeLLphi-305 study.
- Amgen plans to rapidly share DeLLphi-305 interim Phase 3 data with regulators worldwide.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.